Average Co-Inventor Count = 7.72
ph-index = 6
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Janssen Pharmaceutica Nv (23 from 2,078 patents)
2. Tibotec Pharmaceuticals Ltd. (2 from 66 patents)
25 patents:
1. 11267804 - (R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide for inhibiting phosphoinositide-3-kinase activity
2. 11130751 - Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors
3. 10894793 - Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors
4. 10526316 - Quinoxaline and pyridopyrazine derivatives as PI3Kβ inhibitors
5. 10202387 - Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors
6. 10087187 - Imidazopyridazine derivatives as PI3KB inhibitors
7. 10077261 - Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer
8. 9598396 - Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
9. 9150540 - Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors
10. 8889866 - Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
11. 8883837 - Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication
12. 8778966 - Quinolinone derivatives as PARP and tank inhibitors
13. 8404683 - Inhibitors of the interaction between MDM2 and P53
14. 8404713 - Quinolinone derivatives as PARP inhibitors
15. 8377961 - Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and P53